PC
ABUS icon

Polar Capital’s Arbutus Biopharma ABUS Stock Holding History

Polar Capital’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-11,299
Closed -$239K – 276
2014
Q3 		$239K Buy
+11,299
New +$184K 0.01% 265

Other funds holding ABUS

Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
SIA
Sit Investment Associates Minneapolis, Minnesota $5.28B AUM 14.42% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Polar Capital's ABUS Position: Q4 2014 in Review

Polar Capital sold out of Arbutus Biopharma (ABUS) in Q4 2014, closing a stake of 11,299 shares — an estimated $239K sold.

Polar Capital first reported a position in ABUS in Q3 2014 and held it in 1 quarter. The position peaked at $239K in Q3 2014. 49 funds tracked by Wall St. Rank hold ABUS as of Q4 2014.

  • Polar Capital reported no remaining Arbutus Biopharma position as of Q4 2014 after selling out during the quarter.
  • Polar Capital sold 11,299 Arbutus Biopharma shares in Q4 2014, an estimated $239K.
  • Polar Capital first reported a position in Arbutus Biopharma in Q3 2014 and held it in 1 quarter.
  • Polar Capital's Arbutus Biopharma position peaked at $239K in Q3 2014.
  • 49 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q4 2014.

Based on Polar Capital's 13F filing for Q4 2014, filed 17 Feb 2015.